Related Experiment Video

Updated: Sep 30, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Effects of coagulation Factor VII polymorphisms on the coronary artery disease in Japanese: Factor VII polymorphism

Keiko Shimokata1, Takahisa Kondo, Miyoshi Ohno

  • 1First Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.

Thrombosis Research
|July 2, 2002
PubMed

Insights

Certain Factor VII (FVII) gene variations, specifically the M2 and 10 alleles, appear to offer protection against coronary artery disease (CAD) in individuals with normal cholesterol levels.

Area of Science:

  • Cardiovascular Genetics
  • Hemostasis and Thrombosis

Background:

  • Factor VII coagulant activity (FVIIc) plays a role in blood clotting.
  • Genetic variations in the Factor VII (FVII) gene may influence cardiovascular risk.
  • Investigating FVII genetic polymorphisms in relation to coronary artery disease (CAD) is crucial for understanding disease mechanisms.

Purpose of the Study:

  • To examine the association between FVIIc, FVII genetic polymorphisms (R353Q, -323 0/10 bp, HVR4), and the prevalence of CAD.
  • To determine if specific FVII alleles confer protection against CAD in individuals with normal cholesterol levels.

Main Methods:

  • Study included 380 Japanese individuals with normal cholesterol levels undergoing coronary angiography.
  • FVIIc levels were measured.
  • Genotyping for FVII R353Q (M1, M2 alleles), -323 0/10 bp (0, 10 alleles), and HVR4 (H5, H6, H7 alleles) was performed.

Main Results:

  • FVIIc levels were slightly lower in individuals with M1M2/M2M2 genotypes compared to M1M1.
  • Carriers of the M2 and/or 10 alleles showed a reduced likelihood of developing CAD (M2: OR 0.36; 10: OR 0.50).
  • No significant association was found between these alleles and myocardial infarction (MI), nor was HVR4 related to CAD or MI.

Conclusions:

  • The M2 and/or 10 alleles of the Factor VII gene may exert a protective effect against the development of coronary artery disease.
  • These protective effects are observed in individuals with normal cholesterol levels, suggesting a specific role in this population.

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...